Adel Makary

470 total citations
9 papers, 343 citations indexed

About

Adel Makary is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Adel Makary has authored 9 papers receiving a total of 343 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Hematology, 4 papers in Oncology and 3 papers in Genetics. Recurrent topics in Adel Makary's work include Acute Myeloid Leukemia Research (3 papers), Bone health and treatments (2 papers) and Acute Lymphoblastic Leukemia research (2 papers). Adel Makary is often cited by papers focused on Acute Myeloid Leukemia Research (3 papers), Bone health and treatments (2 papers) and Acute Lymphoblastic Leukemia research (2 papers). Adel Makary collaborates with scholars based in United States and Israel. Adel Makary's co-authors include Peter H. Wiernik, Elisabeth Paietta, Martin S. Tallman, John M. Bennett, Jacob M. Rowe, F. Ann Hayes, William R. Friedenberg, Camille N. Abboud, Donna Neuberg and Jane L. Liesveld and has published in prestigious journals such as New England Journal of Medicine, Blood and American Journal of Clinical Pathology.

In The Last Decade

Adel Makary

9 papers receiving 338 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Adel Makary United States	7	257	93	88	88	62	9	343
Mary Papaioannou United Kingdom	10	345 1.3×	117 1.3×	104 1.2×	192 2.2×	65 1.0×	13	456
Velia Bongarzoni Italy	10	238 0.9×	115 1.2×	173 2.0×	24 0.3×	76 1.2×	21	340
S. Couban Canada	3	260 1.0×	31 0.3×	63 0.7×	56 0.6×	85 1.4×	4	324
A Granda Spain	9	397 1.5×	98 1.1×	159 1.8×	39 0.4×	113 1.8×	11	447
Michelle Cummins United Kingdom	7	245 1.0×	26 0.3×	45 0.5×	113 1.3×	118 1.9×	15	344
A Domingo Spain	10	200 0.8×	146 1.6×	36 0.4×	20 0.2×	272 4.4×	22	379
Beatriz Aguado Spain	9	127 0.5×	82 0.9×	92 1.0×	11 0.1×	40 0.6×	22	215
Hasan S. Khalidi United States	10	178 0.7×	49 0.5×	85 1.0×	113 1.3×	79 1.3×	11	332
Masami Yasuda Japan	6	244 0.9×	67 0.7×	76 0.9×	16 0.2×	67 1.1×	15	331
Pilar Robledo Andrés Spain	10	133 0.5×	80 0.9×	27 0.3×	34 0.4×	28 0.5×	18	295

Countries citing papers authored by Adel Makary

Since Specialization

Citations

This map shows the geographic impact of Adel Makary's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adel Makary with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adel Makary more than expected).

Fields of papers citing papers by Adel Makary

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adel Makary. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adel Makary. The network helps show where Adel Makary may publish in the future.

Co-authorship network of co-authors of Adel Makary

This figure shows the co-authorship network connecting the top 25 collaborators of Adel Makary. A scholar is included among the top collaborators of Adel Makary based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adel Makary. Adel Makary is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Luger, Selina M., Jacob M. Rowe, Mark R. Litzow, et al.. (2021). Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial. Leukemia Research. 111. 106736–106736. 3 indexed citations

Berenson, James R., Ori Yellin, John Crowley, et al.. (2010). Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid. American Journal of Hematology. 86(1). 25–30. 15 indexed citations

Yellin, Ori, John Crowley, Adel Makary, et al.. (2009). A088 Overall Survival Among Patients with Multiple Myeloma (MM) Treated with Zoledronic Acid (ZOL). Clinical Lymphoma & Myeloma. 9. S12–S13. 1 indexed citations

Dutcher, Janice P., Sandra Lee, Robert J. Gallagher, et al.. (2004). Phase II study of all-trans retinoic acid in the accelerated phase or early blastic phase of chronic myeloid leukemia: A study of the Eastern Cooperative Oncology Group (E1993). Leukemia & lymphoma. 46(3). 377–385. 7 indexed citations

Rowe, Jacob M., Donna Neuberg, William R. Friedenberg, et al.. (2003). A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 103(2). 479–485. 209 indexed citations

Berg, Karin D., Nooshin K. Brinster, Michael Goggins, et al.. (2001). Transmission of a T-Cell Lymphoma by Allogeneic Bone Marrow Transplantation. New England Journal of Medicine. 345(20). 1458–1463. 52 indexed citations

Makary, Adel, et al.. (1997). Chronic Neutrophilic Leukemia Evolving from a Myelodysplastic Syndrome. Acta Haematologica. 98(3). 163–166. 12 indexed citations

Dutcher, Janice P., et al.. (1995). A phase II study of menogaril (7R-O-methylnogarol) in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group.. PubMed. 9(10). 1638–42. 6 indexed citations

Makary, Adel, et al.. (1991). PlasmapheresisA Therapeutic Option in the Management of Heparin-Associated Thrombocytopenia with Thrombosis. American Journal of Clinical Pathology. 96(3). 394–397. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact